Resumen de acción MCK
McKesson Corporation presta servicios sanitarios en Estados Unidos y a escala internacional.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Narratives
BetaNarratives bring a range of perspectives from our community.
Warren
Based on Analyst Price Targets
Price at publication US$523.37
Updated
Competidores de McKesson Corporation
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$531.10 |
| 52 Week High | US$544.81 |
| 52 Week Low | US$352.34 |
| Beta | 0.45 |
| 1 Month Change | -1.00% |
| 3 Month Change | 5.83% |
| 1 Year Change | 49.85% |
| 3 Year Change | 180.89% |
| 5 Year Change | 303.27% |
| Change since IPO | 3,118.79% |
Noticias y actualizaciones recientes
Recent updates
Is McKesson Corporation (NYSE:MCK) Trading At A 43% Discount?
Mar 14
McKesson: GLP-1 Contributed More Than 1/3 Of Growth
Feb 19McKesson's (NYSE:MCK) Profits May Not Reveal Underlying Issues
Feb 16Investor Optimism Abounds McKesson Corporation (NYSE:MCK) But Growth Is Lacking
Jan 29McKesson: Why The Company Is Too Richly Valued
Jan 19If EPS Growth Is Important To You, McKesson (NYSE:MCK) Presents An Opportunity
Nov 20McKesson: GLP-1 Medications Tailwinds And Massive Share Repurchase
Nov 08Are Investors Undervaluing McKesson Corporation (NYSE:MCK) By 44%?
Oct 30McKesson: Still Trading For A Huge Discount
Sep 06Here's Why McKesson (NYSE:MCK) Has Caught The Eye Of Investors
Aug 21Are Investors Undervaluing McKesson Corporation (NYSE:MCK) By 29%?
Jul 27McKesson: Outlook Remains Positive, I Reiterate My Buy Recommendation
Jun 28Here's Why McKesson (NYSE:MCK) Has Caught The Eye Of Investors
May 23Are Investors Undervaluing McKesson Corporation (NYSE:MCK) By 32%?
Apr 17Do McKesson's (NYSE:MCK) Earnings Warrant Your Attention?
Feb 22McKesson Corporation: Looking Forward To Long-Term Low-Teens EPS Growth
Feb 08McKesson Non-GAAP EPS of $6.90 beats by $0.54, revenue of $70.5B misses by $480M
Feb 01McKesson Corporation's (NYSE:MCK) Intrinsic Value Is Potentially 33% Above Its Share Price
Jan 125 Reasons Why I Am Considering Adding McKesson To My Portfolio
Dec 27McKesson Corporation: Still Trading Below Intrinsic Value
Dec 13Duration: The Time Bomb In Your Portfolio - McKesson And PayPal In Focus
Oct 08McKesson extends distribution partnership with CVS Health
Sep 29An Intrinsic Calculation For McKesson Corporation (NYSE:MCK) Suggests It's 50% Undervalued
Sep 19McKesson to acquire Rx Savings Solutions in $875M deal
Sep 19Cardinal Health, McKesson hit 52-week highs; up 35% and 50% YTD
Aug 15McKesson raises fiscal 2023 adjusted diluted EPS following strong quarterly results
Aug 03McKesson raises dividend by 15% to $0.54/share
Jul 25McKesson Is Still An Attractive Dividend Growth Stock
Jul 10McKesson: Best Of Breed In Drug Distributor Oligopoly
Jun 20McKesson: Still Profitable Without COVID-19 Boosts
Jun 04Rentabilidad de los accionistas
| MCK | US Healthcare | Mercado US | |
|---|---|---|---|
| 7D | -0.8% | -2.3% | -0.7% |
| 1Y | 49.9% | 0.6% | 22.8% |
Rentabilidad vs. Industria: MCK superó al sector US Healthcare , que obtuvo un rendimiento del 1% el año pasado.
Rentabilidad vs. Mercado: MCK superó al mercado US, que obtuvo un rendimiento del 24.9% el año pasado.
Volatilidad de los precios
| MCK volatility | |
|---|---|
| MCK Average Weekly Movement | 2.4% |
| Healthcare Industry Average Movement | 7.4% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Precio estable de las acciones: MCK no ha tenido una volatilidad de precios significativa en los últimos 3 meses.
Volatilidad a lo largo del tiempo: La volatilidad semanal de MCK (2%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1833 | 48,000 | Brian Tyler | www.mckesson.com |
McKesson Corporation presta servicios sanitarios en Estados Unidos y a escala internacional. Opera a través de cuatro segmentos: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions e Internacional.
Resumen de fundamentos de McKesson Corporation
| Estadísticas fundamentales de MCK | |
|---|---|
| Capitalización bursátil | US$70.59b |
| Beneficios(TTM) | US$3.00b |
| Ingresos (TTM) | US$301.51b |
23.3x
Ratio precio-beneficio (PE)0.2x
Ratio precio-ventas (PS)¿Está MCK sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de MCK | |
|---|---|
| Ingresos | US$301.51b |
| Coste de los ingresos | US$289.33b |
| Beneficio bruto | US$12.18b |
| Otros gastos | US$9.18b |
| Beneficios | US$3.00b |
Últimos beneficios comunicados
Dec 31, 2023
Próxima fecha de beneficios
May 07, 2024
| Beneficios por acción (BPA) | 22.81 |
| Margen bruto | 4.04% |
| Margen de beneficio neto | 0.99% |
| Ratio deuda/patrimonio | -338.3% |
¿Cómo se ha desempeñado MCK a largo plazo?
Ver rendimiento histórico y comparativaDividendos
0.5%
Rentabilidad actual por dividendo10%
Ratio de pagos¿Paga MCK dividendos fiables?
Ver historial de dividendos e índices de referencia de MCK| fechas de dividendos de McKesson | |
|---|---|
| Fecha ex dividendo | Jun 03 2024 |
| Fecha de pago de dividendos | Jul 01 2024 |
| Días hasta ex dividendo | 32 days |
| Días hasta la fecha de pago de dividendos | 60 days |
¿Paga MCK dividendos fiables?
Ver historial de dividendos e índices de referencia de MCK